NJII Launches Cell and Gene Therapy Manufacturing Center
The center will be located at NJIT’s Life Sciences and Engineering center and will feature two good manufacturing practices suites that are expected to be completed and operational during the summer of 2020.
The Biopharma Division of the New Jersey Innovation Institute (NJII), a New Jersey Institute of Technology (NJIT) corporation, announced on May 4, 2020 that it is launching BioCentriq, a cell and gene therapy production and manufacturing center in Newark, NJ.
According to a company press release, the center will be located at NJIT’s Life Sciences and Engineering center and will feature two good manufacturing practices suites that are expected to be completed and operational during the summer of 2020.
“BioCentriq will help bring innovative and novel therapies to clinical trials, providing a venue for established companies and start-ups alike. It is also a unique training ground for the workforce of the future,” said Dr. Haro Hartounian, senior vice-president and general manager of Biopharma at NJII, in the press release. “We are grateful to all our partners who have supported us financially and with in-kind donations of equipment and supplies, as well as the industry leaders who serve on our advisory board and lend us their expertise.”
Source: NJII
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
